Related by context. All words. (Click for frequent words.) 74 IIa clinical trial 73 Phase 2a trial 72 Phase 2b trial 72 Phase Ib study 72 phase IIb clinical 71 dose escalation trial 71 phase IIa clinical 71 Phase Ib 71 Phase IIb trials 71 phase IIa 71 oral ridaforolimus 71 Phase 2b study 71 alvespimycin 71 confirmatory Phase III 71 BRIM2 71 Phase 1b trial 70 SUCCEED trial 70 GALNS 70 INCB# [001] 70 phase Ib 70 Phase IIIb clinical 69 Phase 1b 69 Phase Ib II 69 Phase 1b clinical 69 huC# DM4 69 registrational trial 69 Phase #b/#a trial 69 Phase Ib clinical 69 Phase #b/#a clinical 69 pharmacokinetic PK study 69 Quinamed 69 CR# vcMMAE 69 dose escalation 69 BLA filing 69 PEG PAL 69 dose escalation clinical 69 Phase 2a clinical 69 Bezielle 69 phase IIb study 69 dose escalation Phase 68 IMA# 68 Phase Ia 68 oral methylnaltrexone 68 Allovectin 7 68 phase IIb 68 lorvotuzumab mertansine 68 huN# DM1 68 Phase IIb clinical 68 II Clinical Trial 68 Phase 1a clinical 68 forodesine 68 Cloretazine ® 68 eniluracil 68 IIa clinical trials 68 oral prodrug 68 registrational 67 Phase IIa trial 67 PSMA ADC 67 antibody MAb 67 Phase IIb trial 67 IIa trials 67 phase IIb trial 67 R#/MEM # 67 AQ4N 67 Panzem R NCD 67 GLP toxicology studies 67 Phase #b/#a 67 IND submission 67 HGS# 67 BRIM3 67 multicenter Phase 67 Fx #A 67 Alzhemed TM 67 PANVAC VF 67 dose escalation study 67 Capesaris 67 multicenter Phase II 66 Neuvenge 66 ELACYT 66 Phase 1a 66 Phase 2b clinical 66 Phase 2a 66 PF # [002] 66 HuMax EGFr 66 oral deforolimus 66 elotuzumab 66 CoFactor 66 Phase IIb clinical trials 66 phase 2a 66 pertuzumab 66 IMGN# 66 deforolimus 66 evaluating tivozanib 66 YONDELIS 66 Phase IIa trials 66 initiated Phase Ib 66 SNT MC# 66 Archexin 66 Phase IIB 66 ixabepilone 66 histone deacetylase HDAC inhibitor 66 torezolid phosphate 66 novel histone deacetylase 66 ZOLINZA 66 Phase #/#a 66 IIa clinical 66 IIb clinical trial 66 IL# PE#QQR 66 multiple ascending dose 66 Phase III clinical 66 Phase Ib clinical trials 66 assessing T DM1 66 PDE4 inhibitor 66 OncoVEX GM CSF 66 midstage trials 66 Phase IIa clinical 65 CIMZIA TM 65 Troxatyl 65 confirmatory Phase 3 65 tanespimycin 65 HGS ETR1 65 initiate Phase IIb 65 octreotide implant 65 Cloretazine R VNP#M 65 Onalta ™ 65 Phase III confirmatory 65 SAR# [004] 65 ENRICH trial 65 metastatic hormone refractory 65 pomalidomide 65 lintuzumab 65 tubulin inhibitor 65 EDEMA3 65 Proellex TM 65 MEND CABG II 65 ADVANCE PD 65 gemcitabine Gemzar ® 65 Ophena TM 65 JAK inhibitor 65 vidofludimus 65 Trofex 65 ThermoDox R 65 plasma kallikrein inhibitor 65 MGd 65 PRECISE Trial 65 Diamyd ® 65 Phase 1b clinical trials 65 Kamada AAT 65 hypoxia activated prodrug 65 cannabinor 65 Personalized Immunotherapy 65 PEG SN# 65 Hedgehog antagonist 65 Ixempra 65 MAGE A3 ASCI 65 MAA submission 65 fosbretabulin 65 Aflibercept 65 clinical trial 65 NP2 Enkephalin 65 Phase III Clinical Trial 65 MAXY alpha 65 elacytarabine 65 ruxolitinib 65 enzastaurin 65 crizotinib PF # 65 Allovectin 7 ® 65 Dacogen injection 65 Phase IIIb 65 randomized Phase IIb 65 ARIKACE 65 IRX 2 65 trial evaluating PRX# 65 RSD# oral 65 metastatic renal cell 64 Telatinib 64 phase Ib clinical 64 trastuzumab DM1 64 ganetespib 64 generation purine nucleoside 64 Anturol TM 64 Phase 2b clinical trials 64 PXD# 64 desvenlafaxine succinate 64 Phase II 64 rALLy clinical trial 64 ATL# [001] 64 Phenoptin 64 Bayer HealthCare Onyx Pharmaceuticals 64 budesonide foam 64 Phase Ib IIa 64 Zenvia ™ 64 FOLOTYN ® 64 Phase 2a clinical trials 64 Urocidin 64 Spiegelmer ® 64 axitinib 64 LymphoStat B TM 64 Phase IIb 64 Plicera 64 AeroLEF TM 64 nalbuphine ER 64 autologous cellular immunotherapy 64 humanised monoclonal antibody 64 Phase IIIb study 64 Traficet EN 64 relapsed refractory multiple myeloma 64 Phase #/#a trial 64 AAG geldanamycin analog 64 pharmacodynamic PD 64 docetaxel Taxotere R 64 Lucanix R 64 HuMax CD4 64 WX UK1 64 receptor tyrosine kinase inhibitor 64 transmucosal delivery system 64 liposomal formulation 64 Combination REOLYSIN R 64 Annamycin 64 Allovectin 7 R 64 single ascending dose 64 Phase IIa 64 Luveniq 64 Phase III Pivotal 64 Phase III pivotal 64 bavituximab monotherapy trial 64 pharmacokinetic PK 64 sNDA submission 64 omega interferon 64 BrachySil TM 64 Pivotal Trial 64 dosing cohort 64 RhuDex ® 64 initiate Phase 2b 64 OncoGel 64 PROSTVAC ® 64 biliary tract cancer 64 Aplidin 64 Tarceva TM 64 dasatinib Sprycel ® 64 albiglutide 64 virus HCV protease inhibitor 64 compound INCB# 64 Phase III 64 trastuzumab DM1 T DM1 64 PROVENGE sipuleucel T 64 PRT# 64 mertansine 63 relapsed MCL 63 oral picoplatin 63 Phase IIb III 63 multicenter randomized placebo controlled 63 Fibrillex TM 63 ThGRF 63 Proxinium TM 63 Phase 2b Clinical Trial 63 dose cohort 63 KRN# 63 ENDEAVOR IV 63 CRLX# 63 PNP inhibitor 63 evaluating Actimmune 63 mapatumumab 63 Lymphoseek ® 63 SPRYCEL ® 63 GAMMAGARD 63 refractory chronic lymphocytic 63 investigational humanized monoclonal antibody 63 acyclovir Lauriad R 63 Xanafide 63 lintuzumab SGN 63 evaluating mipomersen 63 HCD# [002] 63 Exherin TM 63 Phase III randomized controlled 63 MEND CABG 63 OncoVEX 63 OMNARIS HFA 63 Aurexis 63 VNP#M 63 TLK# 63 APTIVUS 63 VEGFR2 inhibitor 63 Laquinimod 63 IMC #B 63 Corlux 63 refractory APL 63 incyclinide 63 unblinding 63 bortezomib Velcade 63 OvaRex R 63 ProSavin 63 PROVENGE ® 63 dose escalation phase 63 estramustine 63 OHR/AVR# 63 Alocrest 63 EOquin TM 63 Omacetaxine 63 CRMD# 63 treatment naive genotype 63 pivotal bioequivalence 63 Phase IIb Trial 63 metastatic sarcomas 63 Testosterone MDTS ® 63 CCR9 antagonist 63 3 registrational trial 63 UPLYSO 63 MORAb 63 ongoing Phase 1b 63 PDX pralatrexate 63 FOLFOX6 chemotherapy regimen 63 ACTEMRA TM 63 Ketotransdel 63 KNS # 63 multicentre randomized 63 pegylated interferon alpha 63 Amrubicin 63 human IgG1 monoclonal 63 rALLy trial 63 paclitaxel poliglumex 63 Initiate Phase 63 Ceflatonin 63 dirucotide 63 refractory acute myeloid 63 celgosivir 63 brivaracetam 63 targeted radiotherapeutic 63 urocortin 2 63 MT#/MEDI-# 63 tremelimumab 63 overactive bladder AA# 63 CINQUIL 63 Catena ® 63 TELINTRA 63 TOCOSOL Paclitaxel 63 TEMSO 63 rindopepimut 63 Cimzia TM 63 FDA approvable letter 63 decitabine 63 ANYARA 63 dimebon latrepirdine 63 Pivotal Phase III 63 Abiraterone acetate 63 Dose Escalation 63 PEARL SC 63 Asentar 63 obatoclax 63 Multiple Ascending Dose 63 omacetaxine mepesuccinate 63 Simulect 63 neratinib 63 dasatinib Sprycel 63 Zenvia TM 63 GetGoal Phase III 63 CCR5 antagonist 63 placebo controlled clinical 63 Pharmacokinetics PK 63 phase IIIb 63 XL# anticancer compounds 63 BEMA TM LA 63 IMPDH inhibitor 63 APEX PD 63 MEK inhibitor RDEA# 63 BEMA TM Fentanyl 63 metaglidasen 63 Azedra 63 ospemifene 62 DPX Survivac 62 Phase IIa proof 62 PROSTVAC TM 62 orBec 62 alemtuzumab Campath 62 CAELYX 62 AP# [003] 62 teriflunomide 62 farletuzumab 62 Icatibant 62 midstage clinical 62 Phase IIb Clinical Trial 62 vosaroxin 62 oxymorphone ER 62 olaparib 62 PREOS R 62 CHAMPION PCI 62 Degarelix 62 dextromethorphan quinidine 62 ACCLAIM II 62 nab paclitaxel 62 Pralatrexate 62 Glufosfamide 62 Triapine 62 Aurora kinase inhibitor 62 Cimzia ® certolizumab pegol 62 catheter occlusion 62 double blinded placebo 62 Intravenous CP 62 Panzem R 62 Arzerra ofatumumab 62 COMFORT II 62 pivotal Phase III 62 OvaRex ® MAb 62 Vicinium TM 62 Androxal TM 62 cetuximab Erbitux 62 Omnitarg 62 baminercept 62 Hsp# Inhibitor 62 recurrent malignant glioma 62 pradefovir 62 NOX E# 62 #I TM# 62 systemic anaplastic large 62 RSD# 62 ANCHOR trial 62 CML CP 62 Velcade bortezomib 62 IMPACT IMmunotherapy 62 PLK1 SNALP 62 Genz # 62 initiate Phase 1b 62 TroVax ® 62 hereditary deficiency 62 alvimopan 62 CytoFabTM 62 generation PNP inhibitor 62 oral rivaroxaban 62 initiate Phase Ib 62 lumiliximab 62 tezampanel NGX# 62 EDEMA3 trial 62 multicenter clinical 62 EndoTAGTM 1 62 evaluating satraplatin 62 tafamidis 62 ABSORB trial 62 Irinotecan 62 TMC# C# 62 triphendiol 62 Zybrestat 62 palifosfamide Zymafos TM 62 pegylated interferon peg IFN 62 Clolar ® 62 MNTX 62 Genasense ® oblimersen 62 Phase lll 62 amrubicin 62 GRN# 62 ADAGIO study 62 Tarvacin Anti Cancer 62 peginesatide 62 VITAL Trial 62 IND enabling 62 Ceplene/IL-2 62 CCX# 62 galiximab 62 Telik logo TELINTRA 62 Raptiva ® 62 aflibercept 62 QLT# 62 evaluating Nexavar 62 Pimavanserin 62 CBLC# 62 PFO migraine 62 relapsed MM 62 mg/m2 cohort 62 Anthim 62 PNT# 62 ACAPODENE 62 ARRY # 62 DEB# 62 NPC 1C 62 TRO# 62 volociximab 62 PRX # 62 XL# SAR# 62 Aryplase 62 motesanib 62 PI3K/Akt pathway inhibitor 62 TBC# 62 EndoTAG TM -1 62 sunitinib malate 62 BZL# 62 PEG IFN 62 BLA submission 62 CB2 selective receptor agonist 62 Randomized Phase 62 velafermin 62 MEK inhibitor 62 Targretin capsules 62 mRCC 62 PD LID 62 sunitinib Sutent 62 ZACTIMA 62 Vitaxin 62 CLARITY study 62 TMC# [002] 62 Novolimus 62 Files Investigational 62 methylnaltrexone 62 Fodosine 62 confirmatory pivotal 62 trastuzumab Herceptin R 62 Vascular Disrupting Agent 62 HuMax CD# 62 Xcellerated T Cells 62 MYDICAR 62 Bendamustine 62 MKC# MT 62 REOLYSIN ® 62 Telintra 62 KSP inhibitor 62 subcutaneous methylnaltrexone 62 azilsartan medoxomil 62 PROMACTA 62 Mipomersen 62 TG# [001] 62 SNT-MC#/idebenone 62 Curaxin CBLC# 62 OMP #R# 62 icatibant 62 Phase IIa clinical trials 62 ribavirin RBV 62 Apoptone 62 ozarelix 62 Elagolix 62 VALSTAR 62 EFAPROXYN 62 Phase III clinical trials 62 IMC A# 62 Completes Patient Enrolment 62 ThermoDox ® 62 maximally tolerated dose 62 pralatrexate 62 GTC recombinant human 62 Panzem 62 NVA# 62 Lovaxin C 62 Phase III psoriasis 62 Amigal 62 anti EGFR antibody 61 RhuDex 61 Veronate 61 Plenaxis TM 61 tolevamer 61 rhIGF-I/rhIGFBP-3 61 cancer neuroendocrine tumor 61 dependent kinase inhibitor 61 tezampanel 61 Kahalalide F 61 BEZ# 61 recombinant PSMA vaccine 61 RH1 61 initiate Phase IIa 61 lomitapide 61 Temsirolimus 61 abiraterone acetate 61 Valtropin 61 inhaled AAT 61 HER2 positive metastatic breast 61 sitaxsentan 61 SYMMETRY trial 61 LymphoStat B belimumab 61 interferon gamma 1b 61 ILUVIEN ® 61 non nucleoside HCV 61 advanced carcinoid 61 GW# [003] 61 ® natalizumab 61 elagolix 61 Ereska 61 nonclinical studies 61 Meets Primary Endpoint 61 cell lymphoma CTCL 61 leading oral taxane 61 OXi# 61 systemic RNAi therapeutic 61 PS# DARA 61 Viramidine 61 Tanespimycin 61 PrevOnco ™ 61 Sapacitabine 61 viral kinetics 61 OVATURE 61 ALN TTR 61 SILENOR 61 8mg/kg 61 Zavesca r 61 metastatic malignant 61 demonstrated antitumor activity 61 AKT inhibitor 61 TELINTRA R 61 recurrent glioblastoma multiforme 61 Locteron ® 61 Dose Ranging Study 61 pseudobulbar affect PBA 61 TORISEL 61 MVax 61 inhaled formulation 61 Omigard 61 CIMZIA TM certolizumab pegol 61 CYT# potent vascular disrupting 61 Tyrima 61 histamine dihydrochloride 61 PEGylated Fab fragment 61 Pertuzumab 61 Biopharmaceuticals AG 61 Torisel 61 sapacitabine 61 PSN# [002] 61 NLX P# 61 relapsed multiple myeloma 61 ZYBRESTAT 61 Phase #/#a clinical 61 RAV# 61 androgen independent 61 ponatinib 61 Evoltra TM 61 EGS# 61 ALN VSP Phase 61 orally bioavailable 61 CLIRS trial 61 TACI Ig 61 CCX# B 61 TRISENOX 61 Aeroquin 61 MYDICAR ® 61 severe oral mucositis 61 vascular disrupting agent 61 maribavir 61 AMEVIVE 61 adecatumumab 61 placebo controlled Phase 61 SinuNase ™ 61 Solazed 61 FDA Approvable Letter 61 Azedra TM 61 previously untreated follicular 61 SPIRIT FIRST 61 INSPIRE Trial Phase III 61 NASDAQ CXSP announced 61 aurora kinase 61 NSABP C 61 ZEVALIN ® 61 taxane refractory 61 recurrent metastatic ovarian cancer 61 Phase 2b kidney transplant 61 metastatic colorectal carcinoma 61 Dose escalation 61 NGX# 61 Phase 1b dose escalation 61 Hedgehog Pathway Inhibitor 61 ASSERT trial 61 Genasense ® 61 Myocet 61 beta 1a 61 tramiprosate Alzhemed TM 61 fostamatinib 61 ulimorelin 61 randomized Phase 2b 61 CLORETAZINE TM VNP#M 61 multicenter dose escalation 61 Chemophase 61 Oral NKTR 61 glufosfamide 61 CINTREDEKIN BESUDOTOX 61 Clavis Pharma 61 mGluR5 NAM 61 Teysuno 61 Sprycel dasatinib 61 Tocosol Paclitaxel 61 Tesmilifene 61 RezularTM 61 Urocortin 2 61 AVADO 61 anticancer compound 61 trabectedin 61 selective androgen receptor modulator 61 Zerenex 61 BCR ABL inhibitor 61 M Vax 61 Golimumab 61 Phase 2b Study 61 UVIDEM 61 heavily pretreated 61 CUSTOM III 61 including eniluracil ADH 61 recurrent glioblastoma 61 EchoCRT 61 SPARLON 61 SNS# T 61 RANK Ligand inhibitor 61 riociguat 61 Neupro R 61 trabedersen 61 randomized Phase III 61 de novo kidney transplant 61 Jevtana 61 Initiated Phase 61 valopicitabine 61 Phase III trials 61 ocrelizumab 61 Altastaph 61 Ocrelizumab 61 Pivotal Clinical Trial 61 lenalidomide Revlimid R 61 Phase III Trial 61 Initiate Clinical Trial 61 LE SN# 61 recurrent metastatic 61 Factor VIIa 61 biologic therapy 61 budesonide MMX Phase III 61 zanolimumab 61 Tesetaxel 61 Randomized Phase II 61 dexpramipexole 61 radiolabeled TM# 61 Phase IIA 61 non nucleoside inhibitor 61 Phase III multicenter 61 5 fluorouracil leucovorin 61 Dr. Fahar Merchant 61 intranasal formulation 61 Bioral Amphotericin B 61 verteporfin 61 ORENCIA ® 61 Manja Bouman CEO 61 evaluating T DM1 61 Ozarelix 61 EGFR TKI 61 Begins Dosing 61 rALLy 61 leukemia AML 61 reslizumab 61 selective modulator 61 vinorelbine tartrate 61 R sipuleucel T 61 Metastatic Melanoma 61 T DM1 61 ZK EPO 61 AZILECT ® 61 Gleevec resistant 61 mitogen activated ERK kinase 61 BEMA Granisetron 61 MGCD# [001] 61 Phase III TRIST 61 Cloretazine 61 Onrigin 61 docetaxel chemotherapy 61 BIM #A# 61 entinostat 61 Amplimexon 61 Virulizin ® 61 Luteinizing Hormone Releasing Hormone 61 metastatic castration resistant 61 refractory metastatic colorectal cancer 61 balsalazide tablet 61 PREOS 61 Reverset 61 AEG# 61 teduglutide 61 GLPG# 61 Completes Patient Enrollment 61 ILLUMINATE 61 SUTENT ® 61 Lixivaptan 61 Safinamide 61 polymerase inhibitor 61 European Sepsis Trial 61 immunomodulatory therapy 61 Dasatinib 61 TOCOSOL Camptothecin 61 randomized controlled Phase 61 ENMD # 61 neurologic progression 61 eosinophilic asthma 61 CA9 SCAN 61 immunotherapeutic agent 61 Matrix Phase 2b 61 ARIKACE ™ 61 Hepatocellular Carcinoma HCC 61 GOUT 61 BRAF inhibitor 61 MKC# MKC# PP 61 TOLAMBA 61 Triapine R 61 otelixizumab 61 Immunotherapeutic 61 IAP inhibitor 61 nilotinib Tasigna ® 61 immatics 61 oxypurinol 61 EmbraceAC 61 Pegasys plus Copegus 61 VICTOR E1 61 Topotecan 61 Reolysin 61 AzaSite Plus 61 vemurafenib 61 GVAX 60 liposomal doxorubicin 60 drug GAP #B# 60 TAXOTERE R 60 phase IIb III 60 CIMZIA ™ 60 telomerase inhibitor drug 60 oral FTY# 60 severe hypercholesterolemia 60 pralatrexate injection folate analogue 60 adalimumab Humira 60 Theratope 60 HQK 60 LHRH antagonist 60 bicifadine 60 Phase III registrational 60 HGS ETR2 60 investigational immunotherapy 60 personalized immunotherapy 60 Aptivus ® 60 Ophena 60 Besivance 60 Angiocept 60 Taxotere ® 60 REMUNE R 60 ofatumumab 60 AGGRASTAT ® 60 Memryte 60 p# inhibitor 60 interferon beta 1b 60 PRESEPT 60 L BLP# 60 placebo controlled Phase III 60 Marketing Authorisation Application 60 GSK# [001] 60 ANTEGREN 60 Prostate AdenoCarcinoma Treatment 60 double blinded randomized 60 BCIRG 60 FUSILEV ® 60 MoxDuo IR 60 BrachySil 60 alfa 2a 60 investigational monoclonal antibody 60 isoform selective 60 LymphoStat B 60 novel oral anticoagulant 60 PRIMO CABG 60 lexidronam injection 60 thetreatment 60 acetonide FA 60 Octreotide 60 novel VDA molecule 60 Cethrin 60 POSIDUR TM 60 selectin antagonist 60 temsirolimus 60 corticosteroid dexamethasone 60 REVIVE Diabetes 60 Phase 2b 60 tolerated dose MTD 60 CEQ# 60 telaprevir VX 60 GED aPC 60 Q#IR 60 Xeloda ® 60 Advaxis Phase 60 Rhucin R 60 monoclonal antibody conjugated 60 BENLYSTA TM 60 GAP #B# 60 imatinib therapy 60 Certolizumab pegol 60 basal bolus regimen 60 PrevOnco 60 Menerba 60 gemcitabine chemotherapy 60 Tamibarotene 60 NEBIDO 60 ONCONASE 60 AZD# 60 erlotinib Tarceva ® 60 AZILECT R 60 TELCYTA 60 Dyloject TM 60 cutaneous T 60 PRTX 60 dasatinib 60 next generation URAT1 60 ataluren 60 AVASTIN 60 samalizumab 60 generation rotary VAD 60 ASG 5ME 60 paclitaxel Taxol ® 60 LE DT 60 Phase III HEAT 60 Prodarsan 60 Gentamicin Surgical Implant 60 unblinded 60 Sudhir Agrawal D.Phil 60 MERLIN TIMI 60 investigational antiplatelet agent 60 RhuDex TM 60 blinded randomized placebo controlled 60 Cinryze ™ 60 ImmunoVEX HSV2 60 MDV# 60 LibiGel Phase III 60 recurrent herpes labialis 60 BR.# 60 resminostat 60 Combidex 60 HCV protease inhibitor 60 Guanilib 60 Tectin TM 60 plus gemcitabine 60 Valortim 60 Granted Orphan Drug 60 opioid induced bowel dysfunction 60 Initiates Phase II 60 unblind 60 Insegia 60 GLYX 60 Phase 2b randomized 60 REG1 Anticoagulation System 60 refractory cutaneous T 60 Enzastaurin 60 multiple myeloma MM 60 bendamustine 60 NDA submission 60 paclitaxel Taxol R 60 ularitide 60 CYC# 60 AeroLEF 60 eritoran 60 Silodosin 60 intravesical infusion therapy 60 OMAPRO 60 sorafenib Nexavar 60 preclinically 60 EDEMA4 60 Oncotype DX colon cancer 60 EOquin 60 cathepsin K inhibitor 60 LEP ETU 60 diabetic neuropathic pain 60 MIST II 60 solanezumab 60 clinical trials 60 Ixabepilone 60 rasagiline tablets 60 Iloperidone 60 Revlimid lenalidomide 60 OvaRex 60 proteasome inhibitor 60 NDA resubmission 60 Neuromodulation System 60 ganaxolone 60 IAP inhibitors 60 Scopus Affiliation Identifier 60 relapsed refractory 60 afamelanotide 60 Ostarine 60 custirsen 60 Dose Escalation Study 60 SinuNase TM 60 ENDEAVOR III 60 eltrombopag 60 AVN# Phase 60 systemic ALCL 60 refractory CLL 60 Achieves Primary Endpoint 60 Gemcitabine 60 LCP AtorFen 60 cetuximab Erbitux R 60 investigational protease inhibitor 60 Biologics License Application BLA 60 ONTAK 60 tgAAC# 60 ALN PCS 60 ToGA 60 dose cohorts 60 Virulizin R 60 XmAb# 60 Prodarsan ® 60 evaluating REVLIMID 60 Vidaza azacitidine 60 AEGR 60 randomized controlled multicenter 60 DXL# 60 VP# [004] 60 oral treprostinil 60 severe gastroparesis 60 SparVax TM 60 multicenter prospective 60 LCP Tacro 60 Octreolin